Interactive session: alpha emitters, fashion or reality? radionuclides and molecules availability

Full text of publication follows. This introduction to the interactive session will simply be based on statements related to the future of therapy in nuclear medicine with some emphasis on the use of alpha-emitters. Some hypotheses will be developed on topics such as 'How will look nuclear medicine in 2025?', 'Do we have enough information to support the use of alpha in therapy?' 'Does it make sense to develop alpha-labelled molecules without long term financial commitment?', 'Will sufficient amounts of radionuclides available when the drugs will be ready for marketing?', 'Do we know enough about alpha emitters toxicity?', 'Is personalized medicine really the solution of the future of health care?', 'How can we convince authorities about the advantages of alpha labelled molecules?', 'Is the development of alpha RIT more expensive or more difficult than beta RIT?', 'Where are all the beta-emitter under development gone?', 'With alpha-emitters, are we speaking about 2025 or 2050?', 'Will Xofigo be a success?', 'What will be the real role of pharmaceutical companies in radiotherapy?', 'Who are the most afraid about radioactivity, the patients or the authorities?'. The speaker will provide his own opinion about each topic. Will you agree or not with him? What is your opinion? (author)